Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korean Government Steps Up R&D Incentives For Domestic Companies And MNCs

This article was originally published in PharmAsia News

Executive Summary

The Korea Drug Development Fund and the Health Ministry are pursuing two separate projects, but targeting the same goal of helping R&D-focused companies.

You may also be interested in...



Korea's SK Biopharmaceuticals Quietly Sets Its Eyes On The U.S. - And China

SEOUL - After completion of preclinical trials with Chinese contract research organization Shanghai Medicilon Inc., Korea's SK Biopharmaceuticals Co. said Oct. 18 that it plans to file an Investigational New Drug application to conduct clinical trials in the U.S. - possibly in 2014 - for a compound to treat depression and manic bipolar disorder

Korea Tries To Buffer Heavy Price Cuts With R&D Incentives, But Local And Global Pharma Up In Arms

TOKYO - South Korea's Ministry of Health and Welfare announced this week dual measures to drastically cut drug prices, while also committing to support Korea's innovation-focused companies through tax credits and preferential pricing

Korea's Health Ministry Gets In The Act To Generate Korean Innovation For U.S. Markets

SEOUL - South Korea's Ministry of Health and Welfare has selected 21 Korean pharmaceutical manufacturers and 17 medical equipment firms to support these companies in the development of globally competitive new drugs, marketing efforts and U.S. FDA approvals needed for their advancement into the U.S. market

Topics

Related Companies

UsernamePublicRestriction

Register

ID1131511

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel